Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04205916 · ClinicalTrials.gov registry record · Phase 4
A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery
A Phase 4 study of Patient Preference, sponsored by Ophthalmic Consultants of Long Island.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04205916 is a Phase 4 study of Patient Preference that is actively recruiting participants, run by Ophthalmic Consultants of Long Island. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04205916, a Phase 4 study of Patient Preference, is actively recruiting participants, sponsored by Ophthalmic Consultants of Long Island.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and ocular efficacy of Dextenza in combination with an intracameral antibiotic and NSAID in controlling post-operative ocular pain and inflammation compared to standard of care topical therapy in patients undergoing bilateral cataract surgery.
Conditions Studied
Interventions
- DRUG Dexamethasone
- OTHER Standard of care surgery
Study Locations (1)
New York
- Ophthalmic Consultants of Long Island - Garden City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04205916
The ClinicalTrials.gov registry entry for NCT04205916 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ophthalmic Consultants of Long Island, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Patient Preference appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT04205916 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04205916 about?
NCT04205916 is a clinical study titled "A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery". To evaluate the safety and ocular efficacy of Dextenza in combination with an intracameral antibiotic and NSAID in controlling post-operative ocular pain and inflammation compared to standard of care topical therapy in patients undergoing bilateral cataract surgery.
What is the current status of trial NCT04205916?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2019-11-04. Estimated completion is 2020-12-01.
What conditions does trial NCT04205916 study?
This clinical trial studies the following conditions: Patient Preference.
What interventions are being tested in trial NCT04205916?
The interventions under investigation include: Dexamethasone (DRUG), Standard of care surgery (OTHER).
Who is sponsoring clinical trial NCT04205916?
This trial is sponsored by Ophthalmic Consultants of Long Island, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04205916 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Patient Preference
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.